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Dengue is an emerging infectious disease and is spreading world-wide at exponential levels. 
Two billion people in over 100 countries are at risk for infection from one of the four serotypes 
of the dengue virus.  Those infected with dengue may develop diseases such as dengue fever and 
dengue hemorrhagic fever (DHF) and of the 500,000 cases that progress to DHF each year, more 
than 22,000 will result in fatality.   Discovering new antivirals to treat DHF is essential to 
reducing  this  disease  burden.    Here,  we  have  developed  a  cytopathic  effect-based  high- 
throughput screen (HTS) to discover possible inhibitors of Dengue viral infection of hepatocytes 
in vitro.  Dengue virus infection of hepatocytes induces massive cell death, “cytopathic effect 
(CPE)”, which we converted into a screening assay whereby inhibitors of Dengue infection 
prevent cells from dying.   In this assay, the viral induced CPE is quantitated by monitoring 
cellular ATP levels, which positively correlates with cellular viability. ATP in the cell culture 
will drive the oxidation of luciferin resulting in the emission of light that is quantitated using a 
luminometer.  The assay is simple and highly reproducible yielding a screening window 
coefficient, Z- factor, of 0.78±0.12 between plates.    The Z-factor is a statistical parameter 
commonly accepted as an assay quality assessment and is reported as a value 0 to 1 and 
anything over 0.5 is considered excellent quality.  This assay is advantageous to current 
 
v  
methodology as it simultaneously screens possible inhibitory compounds while controlling for 
any unwanted toxicity triggered by these drugs.  Our initial HTS of a 288 small compound 
library yielded a total of eleven hits that prevented the CPE of dengue infection.  Further 
evaluation with an immunofluorescence assay showed that two of these compounds, 
Streptovitacin A and Nagilactone C, are highly potent inhibitors of dengue infection.  At 
effective inhibitory doses, they did not appear to be cytotoxic, and therefore both of these 
compounds are possible antivirals and could be used to elucidate various cellular mechanisms 
utilized during the dengue life cycle.  The discovery of these two inhibitors demonstrates the 
efficacy of our newly developed assay and the public health significance of this project. 
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1.0 INTRODUCTION 
 
 
 
 
 
 
1.1 DESCRIPTION OF THE PROBLEM 
 
 
 
 
Two billion people in over 100 countries are at risk for infection from one of the four serotypes 
of Dengue virus (DEN) making it the most prevalent mosquito-borne virus worldwide (10, 23). 
Those infected by this virus may develop diseases ranging from the self-limited febrile illness 
dengue fever (DF) to the more severe dengue shock syndrome (DSS) and dengue hemorrhagic 
fever (DHF). Of the 500,000 cases that progress to DHF each year, more than 22,000 will result 
in fatality (31).  Unfortunately there are currently no vaccines or antiviral therapies approved for 
the treatment of infection.  Novel therapeutics, therefore, are in urgent need to fight the infection. 
 
 
1.1.1    Dengue Virus 
 
 
 
 
DEN is an arthropod-borne virus (arbovirus) and is transmitted to humans by the imbibing of a 
mosquito, more specifically the Aedes genera of mosquito and most often from Aedes aegypti 
(31).  It is an enveloped positive sense single-stranded RNA virion that belongs to the genus 
Flavivirus,  family  Flaviviridae.    The  10.7kb  genome  of  DEN  is  enclosed  in  the  structural 
proteins, capsid (C), membrane (M) and envelope (E) forming the ~50um spherical lipid- 
enveloped particles (23). 
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Figure 1. Dengue Genome and Polyprotein. 
 
 
 
The positive-sense single-stranded genome of DEN is translated into a polyprotein 
containing three structural and seven nonstructural proteins.  This polyprotein contains several 
transmembrane regions and is integrated into the lipid bilayer of the ER where it is cleaved by 
both host and viral proteases (Figure 1) (1, 24).  Virus assembly occurs in the ER after cleavage 
and the virions are exocytosed through the Golgi secretary vesicle system (24). 
 
It has not yet conclusively been shown what the primary sites of infection are by the virus 
given that viral antigens are found in many host cell lines during infection (8).  In reality, dengue 
has abroad cellular tropism as it uses a n umber of ubiquitous receptors and cellular factors for 
entry including DC-SIGN, manose receptor, heparan sulfate, GRP78/BiP, CD14, Hsp90, and a 
37/67-kDa high affinity laminin receptor (3, 4, 13, 18-20, 23, 28, 29).   After the virion has 
attached to the required cellular receptors it is thought to migrate to pre-existing clathrin coated 
pits on the host cell before it enters via clathrin-mediated endocytosis (30). Once inside the 
3  
endosomes, a reduction in pH triggers fusion of the E protein with the lipid membrane and the 
releasing of the viral nucleocapsid into the cell cytosol (1, 23). The positive-sense RNA is 
translated  into  a polyprotein  which  is  cleaved  by both  viral  and  host  proteases  and  RNA- 
dependent-RNA-polymerase (RDRP) will replicate the viral genome of DEN. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Dengue Replication Cycle. 
 
 
 
1.1.2    Dengue Pathogenesis 
 
 
 
 
DEN is now endemic to tropical and sub-tropical regions and over the past 20 years has vastly 
increased in both cases and countries infected (9).    The regions that are most susceptible to 
infection are the Asia–Pacific, the Americas, the Middle East and Africa (11).    In addition, 
recently there has been a 4 fold increase in dengue cases reported in the Americas (12). Since 
many of these regions lack dengue surveillance, these shocking statistics are probably an under 
4  
estimate to the true problem.   There are four serotypes (DV1-4) all of which share the same 
structural and pathogenic characteristics but have distinct genetic features. It is thought that 
DV2 and DV3 contribute most to the severity of disease (11). 
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Figure 3. Dengue Pathogenesis flow chart.  Once infected individuals will either develop symptoms 
or remain asymptomatic before viral clearance. For those who become symptomatic, they could either 
develop “dengue fever” or maintain an undifferentiated fever.    Some will progress from dengue fever to 
dengue hemorrhagic fever and dengue shock symptom which may lead to death. 
 
 
 
Generally, those infected by this virus may develop diseases ranging from the self-limited 
febrile illness DF to the more severe DSS and DHF (Figure 3). Of the 500,000 cases that 
progress to DHF each year, more than 22,000 will result in fatality (31). Symptoms for DF 
generally resemble a severe flu but can vary between cases and also according to age.   For 
example, young children are often asymptomatic or have undifferentiated fever whereas the 
disease in older children and adults the disease is more severe (11).  However the majority of 
deaths related to dengue infection are in young children, increasing the years of potential life lost 
(YPLL) and overall disease burden. 
5  
The overall pathogesis of dengue infection is poorly understood. For example, it has not 
conclusively been shown what the primary sites of infection are and exactly what cells are 
involved in disease progression.  However, recent data indicates that dengue may infect liver 
sinusoidal endothelial cells and hepatocytes in vivo suggesting that the liver may play a key role 
in dengue pathogenesis (34). 
 
 
1.1.3 Dengue Prevention and Treatment 
 
 
 
 
One might imagine an obvious solution to preventing this global disease could be to 
eliminate the mosquito vector; however mosquito control measures have failed on numerous 
occasions and attempts often create more problems (12).  For example although eradicating 
mosquitoes will reduce the amount of infections that occur, it also limits the number of people 
who possess antibodies to fight the infection.   This limitation in herd immunity may cause 
detrimental effects if the mosquitoes have a chance to multiply at exponential levels for example 
after a natural disaster. 
Although a few compounds, ribavirin and mycophenolic acid, have shown to be potent 
inhibit Dengue infection in vitro, there are no antiviral therapies approved for the treatment of 
infection (27).   Since there is no vaccine to prevent infection novel therapeutics are in urgent 
need to treat the disease. High-throughput screening assays are a rapid, easy, cost-efficient way 
to evaluate large libraries of compounds to find possible inhibitors of infection from viruses. 
One  such  system,  the  CPE-based  high-throughput  assay,  has  proven  to  be  robust  and 
reproducible systems to screen inhibitors for a number of viruses including influenza, hepatitis 
C, bluetongue, human rhinovirus and severe acute respiratory syndrome coronavirus (SARS) (5, 
16, 21, 22, 26).  Because we have observed a similar cytopathic effect in DEN, we hypothesized 
6  
that  novel  inhibitors of DEN  infection  could  be identified through  a similar  CPE-based 
larger scale screening assay. 
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2.0 STATEMENT OF THE PROJECT 
 
 
 
 
 
 
While propagating the DV2, we noticed that it induces rapid cell death in the human hepatoma 
cell line, HuH7.5.1.  T his virus-induced cell death (cytopathic-effect) can be converted into a 
screening assay in which inhibitors of Dengue infection will prevent cells from dying.  In this 
assay, viral induced cytopathic effects are quantitated by monitoring cellular ATP levels, which 
positively correlate with cellular viability. ATP in the cell culture will drive the oxidation of 
luciferin resulting in the emission of light that is quantitated using a luminometer. Since this 
assay measures overall cellular viability, it simultaneously screens for inhibitory compounds 
while controlling for unwanted cytopathic effects caused by the drugs (drugs that are toxic will 
add  to  the  viral  educed  cytopathic  effect).    We  hypothesize  that  novel  inhibitors  of  DEN 
infection can be identified through a cytopathic effect-based larger scale screening.  To test the 
hypothesis, our objectives were: 
Specific  Aim 1 : The  development and optimization of a  CPE-based high-throughput 
screening assay to identify novel inhibitory compounds of Dengue infection of hepatocytes. 
Specific Aim 2: Screening a small compound library and the characterization of two novel 
inhibitors Streptovitacin A and Nagilactone C. 
We believe that this high-throughput screen will contribute to developing “lead” compounds of 
novel antivirals and could be used to elucidate mechanisms of the dengue life-cycle. 
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3.0 MATERIALS AND METHODS 
 
 
 
 
 
 
3.1 PROPAGATION AND IDENTIFICATION OF PROTOTYPE VIRUS 
 
 
 
 
3.1.1    Cell lines and Reagents 
 
 
 
 
Both Vero and C6/36 cells were purchased from ATCC and maintained as instructed by the 
manufacturer.  The Huh7.5.1 line was generated from a cured HCV replicon and was provided 
by Dr. Francis Chisari (Scripps Research Institute). All cell lines were maintained in DMEM 
supplemented with 5% Penicillin and streptomycin, 1% NEAA and 10% fetal bovine serum 
(FBS) (Gemini Bio-Products). 
Antibodies were produced from hybridoma cells purchased from ATCC (HB-112 and HB-
114). Both of these cell lines were maintained as instructed by the manufacturer.  Secondary 
antibodies were purchased from molecular probes (Invitrogen).  M ycophenolic acid and 
Bafilomycin A were purchased from Sigma. 
 
 
3.1.2    Propagation of Virions 
 
 
 
 
Prototype Dengue strains were propagated in either Vero or C6/36 cells depending on their 
passage in previous cell lines.  Cells were seeded 24 hour s prior to infection in a T175 cell 
culture flask.  When the cells had reached ~60-80% confluence they were infected with virus at 
9  
an MOI of 0.01.  The cells were incubated for 7 days or until they began to die from the 
cytopathic  effect  caused  by  the  virus.    After  propagation,  the  virus  containing  media  was 
collected and centrifuged at 1500g for 5 minutes to remove extracellular debris.  The supernatant 
was then passed through a 0.22um filter syringe and alloquated before it was frozen at -80C for 
long term storage. 
 
 
3.1.3    Western Blot Assay 
 
 
 
 
Cell Lysates (25µl) were subjected to electrophoresis through a 8% sodium dodecyl sulfate 
(SDS)-polyacrylamide gel and transferred to nitrocellulose membranes by using the Mini Trans- 
Blot electrophoretic transfer cell (Bio-Rad Laboratories, Richmond, Calif.) in transfer buffer 
(15.6mM  Tris  base,  120mM  glycine).    The  membrane  containing  transferred  proteins  was 
blocked  with  5%  skim  milk  in  Wash  Buffer  at  room  temperature  for  10 m inutes.   T he 
membranes were incubated for 1h at room temperature with either a monoclonal antibody 
produced by hybridoma cell line HB-114 (2H2) or HB-112 (4G2) against and actin at a dilution 
of 1:10and 1:500 in 5% skim milk in Wash buffer, respectively. After incubation for 2 h at room 
temperature, membranes were incubated with horseradish peroxidase-conjugated mouse anti- 
goat IgG1:500 in 5% skim milk in Wash buffer for 1 h at room temperature. Finally, the signal 
was developed using the ECL. 
 
 
3.1.4    Immunofluorescence Assay 
 
 
 
 
All cells were seeded 24 hours before infection to reach an 80% confluence.   T he cells were 
washed for 5 minutes 3 times with 1X PBS.  After washing the cells, they were fixed using a 2% 
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paraformaldehyde and permeablized using 0.2% Triton or fixed and permeablized and fixed with 
 
100% methanol. The dengue envelope proteins were detected using a 1:10 dilution of the 4G2 or 
 
2H2  primary  antibody  isolated  from  a  hybridoma  culture  and  1:500  of  a  HRP  secondary 
antibody.  Nuclei were stained using Draq5 or DAPI as indicated. 
 
 
3.1.5    Virus Tittering (Reed & Muench method) 
 
 
 
 
Viruses were tittered using a Reed & Muench Tissue Culture Infectious Dose50 Assay 
(TCID50/ml) system.  A n example of the application of this assay is demonstrated in Figure 6. 
Cells were seeded so that they will reach 80% confluence in 24 hour s.  O n the day of the 
experiment, serial dilutions of virus are made in media and a total of 8 wells were infected with 
each serial dilution of the virus.  After 48 hours incubation, an IFA was completed for all of the 
used wells.  T he wells were then examined under an epifluorescence for any positive wells. 
Anything greater than one positive cell indicated a positive infected well.  Interestingly though 
where one cell is infected there is a small grouping of infected cells surrounding forming a foci. 
 
 
 
 
 
3.2 LUCIFERASE-BASED HIGH THROUGHPUT SCREEN 
 
 
 
 
3.2.1    Cytopathic Effect - Luciferase Reagent 
 
 
 
 
The CPE Luciferase reagent was prepared by combining a 1ml of a 5X D-Luciferin Stock 
Solution  (1mM  D-luciferin,  25mM  Glycylglycine,  10mM  DTT),  1ml  luciferase  enzyme 
(1mg/ml),  0.5ml  250mM  Glycylglycine  and  3.5ml  H2O  in  9ml  Luciferase  Assay  Buffer 
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(25mMGlycylglycine pH 7.8, 15mM Potassium Phosphate pH 7.8, 15mM MgSO4, 4mM EGTA 
in H2O).  The solution was then aliquoted into 1.8ml eppendorf tubes and kept at -80 C for long- 
term storage. 
 
 
 
3.2.2    CPE-based high-throughput screening assay. 
 
 
 
 
Huh7.5.1 cells are counted with a hemacytometer and 1.8*104 cells are seeded per well in a 9 6 
well format 24 hours prior to the experiment.  After cells had reached an 80% confluence they 
were infected with DV2 in the presence or absence of a compound for two hours.  After the 
infection the virus was replaced with fresh compound containing media.  After a set duration, the 
CPE solution was thawed at room temperature just before the assay.  All media was removed 
from the cells.  A 5X passive lysis buffer was diluted to 1X in 1X PBS and then 70μl of the 1X 
lysis buffer was added to each well.  The plates were incubated in the 37 degree incubator for 10 
minutes and then 50μl of the lysate was transferred to a luminometer plate.  At least 50μl of the 
CPE buffer was then quickly added to all wells in the luminometer plate and the luciferase 
reading was quantified with an Auto Lumat luminometer. 
 
 
3.2.3    Cell Culture Derived (HCVcc) Luciferase Assay 
 
 
 
 
Production procedure of HCVcc (JFH-1 strain) expressing firefly luciferase that was inserted 
between NS5A and NS5B (sequence available upon request) was described elsewhere (17, 32, 
33).  A 5X passive lysis buffer was diluted to 1X in 1X PBS and then 70μl of the 1X lysis buffer 
was added to each well.  The plates were incubated in the 37 degree incubator for 10 minutes and 
then 50μl of the lysate was transferred to a luminometer plate.  A t least 50μl of the LARII 
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luciferin buffer was then quickly added to all wells in the luminometer plate and the luciferase 
reading was quantified with an Auto Lumat luminometer. 
 
 
3.2.4    New Castle Disease Virus-Green Fluorescence Protein Assay 
 
 
 
 
NDV-GFP virus production- NDV-GFP virus was a generous gift from Dr. Chris Basler (Mount 
Sinai School of Medicine, NYC) and was produced in 10-days old embryonated eggs (Charles 
River Laboratories International, Inc. Wilmington, MA).  The inoculated eggs were incubated for 
two days at 37 οC and the allantoic fluid containing virus was harvested, filtered and stored in - 
80οC until use.  The use of this virus has been described elsewhere [48]. 
 
 
NDV infection assay- 1.8*104Huh7.5.1 cells were seeded in 96 w ell plates.  Cells were 
washed with PBS and 20 µl (MOI 1) of NDV-GFP virus was added in 180 µl of PBS (with Ca 
and Mg) and left at 37 οC for 1 hour. Cells were then washed with PBS and imaged. GFP signal 
started to appear after 12 hours but peaked at 24hours post-infection. DAPI was added to stain 
nuclei. 
 
 
 
 
 
3.2.5    High-Throughput Screening Assay Data Analysis 
 
 
 
 
The percentage of inhibition was calculated using a formula: % inhibition= (RLUexp- 
RLUmin)/(RLUmax-RLUmin)*100 where RLUexp represents the luciferase counts obtained 
from inhibitor treated wells, and RLUmax typically comes from uninfected wells whereas 
RLUmin comes from DEN infected and treated with DMSO. 
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Since signal-to-background does not report any information on data variation, a screening 
window coefficient, called "Z- factor," was used here to show the reproducibility and robustness 
of the assay (35).  T he Z’ factor = 1−((3SdDevS+3 SdDevN)/(|MeanS – MeanN|)) where S is the 
luciferase counts from uninfected wells and N is the counts from infected wells.  The Z’ values 
are calculated taking luciferase counts in triplicate from within the same experiment.  The signal- 
to-background was calculated as a ratio between the RLUmax/RLUmin.  Our data showed an 
average Z-factor of 0.78±0.12 between plates. 
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4.0 RESULTS 
 
 
 
 
 
 
We hypothesize that novel inhibitors of DEN infection can be identified through a larger scale 
screening. To test the hypothesis, our objectives were: 
Aim 1: Propagation and tittering of prototype strains of Dengue virus. 
 
Aim 2 : The development and optimization  of a CPE-based high-throughput screening 
assay to identify novel inhibitory compounds of Dengue infection of hepatocytes. 
Aim  3:  Screening a small compound library and the characterization of two novel 
inhibitors Streptovitacin A and Nagilactone C. 
 
 
 
 
 
4.1 SPECIFIC AIM 1 RESULTS 
 
 
 
 
Aim 1: Propagation, detection and tittering of prototype strains of Dengue virus. 
 
 
 
Until recently our lab was primarily focused on hepatitis C virus work.  However we recently 
decided to branch out and begin working on Dengue, another RNA virus that that belongs to the 
Flavivirus family.  We obtained all four serotypes of prototyped virus as a gift from Dr. Ernesto 
Torres  De  Azeved  Marques  Jr.    The  following  experiments  outline  the  steps  we  took  to 
propagate the newly obtained virus using Vero and C6/36, two cell lines that were new to our 
lab, and methods  we utilized to confirm the infection of our cell lines.   In  addition these 
15  
experiments show that we successfully produced antibodies from hybridoma cells received from 
 
ATCC. 
 
 
 
 
4.1.1    Experimental Scheme of Dengue propagation and detection 
 
 
 
 
Because we obtained only a small quantity of DV2 (<1ml) we first needed to amplify the virus to 
obtain enough to complete several experiments.  The DV2 Thailand strain was propagated as 
illustrated in Figure 4.  Briefly, C6/36 cells were seeded 24 hours prior to infection in a T175 cell 
culture flask.  W hen the cells had reached 80% confluence they were infected with virus at an 
MOI of 0.01.  The cells were incubated for 7 days before the media was collected.  Several 1 ml 
aliquots were then prepared to prevent the loss of viable virus from repeated freeze-thaws.  After 
harvesting the virus we infected Vero and C6/36 cells to determine if we could distinguish 
infection with our hybridoma produced antibodies on an IFA and western blot. 
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Figure 4. Overall scheme of the propogation and identification of prototype strains of DEN.  C6/36 
mosquito cells are infected with the prototype virus at an MOI of 0.01 and incubated for ~7days.  The virus 
can then be identified on a western and IFA using antibodies produced by hybridoma cells. 
 
 
 
 
4.1.2    Detection of the DV2 Infection of Vero and C6/36 
 
 
 
 
We were able to detect infection from the newly propagated virus using both an IFA and western 
blot (Figure 5). As shown in Figure 5A there was no prM/E signal in the mock (media) infection 
for both C6/36 and Vero cells, however there are still a large number of viable cells present as 
indicated by the blue DAPI nucleus stain.  Conversely, in the cells infected with the DV2 strain 
we see a distinct red signal surrounding the nucleus (cytoplasm) of the cell which is a distinct 
characteristic for RNA viruses such as Dengue.   Incubation of the western blot (Figure 5B) with 
the hybridoma produced prM/E antibodies indicated a band in both positive lanes, but not the 
negative lanes of C6/36 and Vero cells.  Β-actin was included as a loading control. 
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Figure 5. The infection of propagated virus in C6/36 and Vero cells. (A) IFA of C6/36 and Vero cells 
infected or uninfected (Mock) with the DEN2 virus.  The prM/E was detected with the 4G2 primary antibody 
conjugated with Alexa Fluor 568 as a secondary. (B) Western blot of C6/36 and Vero cells infected (+) of 
uninfected (-) with the DV2 clinical isolate virus. The prM/E was detected in both of these infected cell lines 
with the 4G2 primary antibody, but not in the uninfected. β-Actin was used as a loading control. 
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4.1.3    Tittering of DV1-4 using the Reed and Muench method to calculate TCID50/ml. 
 
 
Since we had shown that we could detect infection of DV2 on an IFA, we attempted to propagate 
and titer all 4 serotypes of DEN.  To this aim we used the Reed and Muench method to calculate 
a TCID50/ml as demonstrated in Figure 6.   Briefly, serial dilutions are made of the virus and 
then used to infect 8 wells of Vero cells.  The wells are then counted as infected or uninfected 
and these values are extrapolated into a virus titer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Virus Titering using an IFA and the Reed & Muench method 
of calculating the TCID50/ml. The TCID50 is calculated using the formula: 
 
lgTCID50=lgdo + (f + 1) lgR 
 
 
Where do is the dilution that gives you a positive well , f is a number derived 
from then number of positive wells calculated by a moving average and R is 
the dilution factor. 
 
 
 
 
As shown in Table 1, we obtained similar concentration to the initial for all viruses except the 
Vero propagated DV1 Hawaii strain.  Only the DV2 serotype caused a cytopathic effect during 
the propagation procedure the remaining strains were propagated for a total of 7 days before 
harvesting. 
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Table 1. TCID50/ml of each strains of propagated prototyped virus.   Initial concentrations as well as 
newly propagated concentrations are indicated.  The virus propagation was continued using the same cell 
lines passed by the previous lab. 
Original 
Concentration New Concentration Cell Line 
Serotype Strain (FFU/ml) (TCID50/ml) propagated 
DENV1 HAWAII 2.67E+06 1.00E+04 Vero 
DENV2 Thailand 16681 4.20E+06 3.16E+06 C6/36 
DENV3 H-87 7.60E+04 1.00E+06 C6/36 
DENV4 H-241 6.40E+04 6.31E+04 C6/36 
 
 
 
 
 
 
4.1.4    The Infection of Human Hepatoma Cell Lines Huh7.5.1 and HepG2 
 
 
 
 
After we had determined the titer for each virus we then attempted to infect human hepatoma cell 
lines Huh7.5.1 and HepG2 with the DV2 serotype.  In this experiment it seems Huh7.5.1 cells 
(Figure 7A left panel) are either more susceptible or permissive for infection from DEN than the 
HepG2 cells (Figure 7A right panel).  Similar to the infection of Vero and C6/36 cells, we 
observed viral antigen isolated in the cytoplasmic region surrounding the nucleus which is a 
signature for RNA virus.  We confirmed the infection of Huh7.5.1 cells in the IFA by a western 
blot (Figure 7B).   We also tested increasing dilutions of the antibody to determine the minimal 
amount necessary to show strong results. 
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Figure 7. Propagated DV2 virus infection of hepatocytes cell lines was confirmed by IFA and Western 
Blot A ssay. (A) IFA of Huh7.5.1 and HepG2 cells infected or uninfected with the DEN2 prototype virus. 
The prM/E was detected with the 4G2 primary antibody conjugated with Alexa Fluor 568 as a s econdary. 
(B) Western blot of Huh7.5.1cells infected (+) of uninfected (-) with the DV2 clinical isolate virus. The 
prM/E was detected in these infected cell lines with the 4G2 primary antibody.  In addition we attempted to 
use dilutions of the antibody to test the concentration effectiveness. 
 
 
 
 
 
 
 
4.2 SPECIFIC AIM 2 RESULTS 
 
 
 
 
Aim 2 : The development and optimization  of a CPE-based high-throughput screening 
assay to identify novel inhibitory compounds of Dengue infection of hepatocytes. 
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While propagating the DV2 virus, we noticed that there is a cytopathic effect (Figure 8A).  The 
cells were stained 24 a nd 72 hour s post infection (PI) with trypan blue, a die that will easily 
defuse into cells that have a d amaged cellular membrane but not cells that are viable.  B oth the 
Mock and DV2 infected cells appear >95% viable after 24 hours, however at 96 hou rs PI, the 
DV2 infected wells have lost over 80% of the total monolayer. 
 
 
4.2.1    Experimental Scheme of the Cytopathic-Based High-Throughput Screening Assay 
 
 
 
 
This virus-induced cell death (cytopathic-effect) was converted into a s creening assay in which 
inhibitors of Dengue infection will prevent cells from dying.   In this assay, viral induced 
cytopathic effects are quantitated by monitoring cellular ATP levels, which positively correlate 
with cellular viability.  ATP in the cell culture will drive the oxidation of luciferin resulting in 
the emission of light that is quantitated using a luminometer.  As shown in Figure 8B, there is a 
window of high luciferase readings in uninfected cells compared to low levels in infected known 
as the signal-to-background ratio.   If a compound (compound A) prevents the infection of 
dengue, then we expect to see luciferase readings significantly higher than the noise.  However if 
the compound (compound B) causes additional cytotoxicity we will see readings at or below that 
of the untreated infected cells. 
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Figure 8. Cytopathic effect of the Dengue virus on HuH7.5.1. (A). DEN infection of human hepatoma cell 
line Huh7.5.1 (MOI 1) induced massive cell death at 72 hours post-infection (PI).   Huh7.5.1 were seeded in a 
96 well format at a concentration of 1.8*104  and 72 hours after infection all wells were exposed to 1% Trypan 
Blue.  We observed 80-90% cell death in the infected as compared to uninfected. (B) Overall design of the 
screening assay.  The  cell  death resulting from dengue  infection causes a  loss  of  cellular  ATP  and  by 
monitoring the ATP levels in vitro we can deduce the level of viral infection and replication before and after 
drug treatments. Huh7.5.1 cells are exposed to possible candidate drugs and infected with the dengue virus at 
an MOI of 1. After 48 hours infection the cells are lysed in a buffer containing both the luciferase enzyme and 
luciferin substrate. Any remaining ATP in the cell culture will drive the oxidation of luciferin resulting in the 
emission of light that is quantitated using a luminometer. 
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4.2.2 Optimization of Multiplicity of Infection and Duration of the Cytopathic Effect- 
 
Based HTS Assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Optimizing the concentration of virus and duration of the CPE-screening assay. Huh7.5.1 
cells were infected with different multiplicities of infection (MOIs) for various lengths of time before taking 
a luciferase reading to find the shortest duration with the highest signal-to-background ratio. 
 
 
 
 
Figure 9 shows the optimization of this screening assay to find the MOI with the broadest signal- 
to-background ratio in the shortest duration.  Having a broad signal-to-background will increase 
the overall sensitivity of our assay and allow us to find hits that have a high probability of 
inhibiting infection.  The duration is important to optimize as well since too short of an infection 
will not cause cell death and too long of a period will cause the chemicals to degrade and lose 
effect.  We therefore reasoned that infecting cells with an MOI of 1 for a total of 72 hours is an 
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optimal condition.  Although the signal/noise ratio is >16, which is somewhat lower than the 22 
fold at 96 hours, it is still a much broader window than at 48 hours or at any of the other MOIs.    
    
 
 
 
The optimization experiment from Figure 9 was repeated using IFN-α, a known inhibitor 
of dengue infection, to show that the assay will in fact detect inhibition (Figure 10).  Although 
the inhibition was lowest at an MOI of 1 and duration of 72 hours, we reasoned that this 
demonstrated the robustness of the assay, as it will only show positive hits that inhibit infection 
more than a known non-specific inhibitor.    
Figure 10. Efficiency of the CPE-based screening assay to show inhibition. IFN-α, a known non-specific 
inhibitor of dengue infection was used to show that the CPE assay will detect the inhibition of infection.  
Cells were infected using the same conditions as in the optimization experiment.  An MOI of 1 would be 
optimal to ensure that only the compounds with strongest inhibition are defined as positive hits. 
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Since this assay measures overall cellular viability, it simultaneously screens for 
inhibitory compounds while controlling for unwanted cytopathic effects caused by the drugs 
(drugs that are toxic will add to the viral educed cytopathic effect). This is demonstrated with 
Bafilomycin A in figure 11.  In a TCID50/ml assay (Figure11A), Baf A inhibited the infection of 
nearly 100%, however Baf A causes immense toxicity to the hepatocytes (Figure 11B).  Since 
our assay measures total cellular viability after treatment with compounds and virus, this drug 
would have been screen out (Figure 11C).         
   
 
 
 
Figure 11. Demonstration of the assays simultaneous detection of inhibition and toxicity. Baf A inhibits 
nearly 100% infection in a TCID50 assay (A), however it caused cell death in over 50% of the cells by 72 
hours post infection (B).  Because our assay monitors cell viability and inhibition together, this compound 
would have been screened out (C). 
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4.3 SPECIFIC AIM 3 RESULTS 
Aim 3:  Sreening a small compound library and the characterization of  two novel 
inhibitors Streptovitacin A and Nagilactone C. 
4.3.1 Screening a Small Compound Library 
Results from the initial CPE-based high-throughput screen on the National Cancer Institute 
(NCI) 264 c ompound library are shown in Figure 12.  A total of 11 c ompounds inhibited the 
infection over our 50% cut off value.  The compounds that fell below 0% mark are as such 
because of the high level of toxicity.  Two of the eleven compounds, Streptovitacin A and 
Nagilactone C, were shown to inhibit infection with an IFA and were therefore further 
characterized in the following experiments.  
 
 
Figure 12. High-throughput Screening of Small Compound Library. The initial high throughput screen 
of the NCI 264 small compound library yielded 11 positive hits (over 50% inhibition).  The two compounds 
that were found to inhibit in the following immunostaining assays, Streptovitacin A and Nagilactone C, are 
shown. 
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4.3.2    Validation of the Positive Hits with an Immunofluorescence Assay 
 
 
 
 
We attempted to validate the positive hits from the high-throughput screen using an IFA.  Light 
microscopy images (Figure 13 left) were taken to show the cell viability and morphology after 
exposure to these chemicals.  Untreated cells infected with media (mock) or DV2 48 hours prior 
to staining were used as a control.  There is no fluorescent signal in the mock infected cells, 
however the DV2 cells show a high level of fluorescence that is localized to the cytoplasm 
surrounding the cell nucleus.  Compound 377 B 11 (streptovitacin A) inhibited infection at all 
concentrations tested and 3977 G 11 (nagilactone C inhibited at all except the lowest 1μM 
concentration.  W e included results from one of the other compounds tested (3978 G8) as a 
control as it did not inhibit infection at any of the concentrations. 
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Figure 13. IFA of two positive hits from the CPE assay. Compounds 3977 B 11 and G11 but not G8 
inhibited DEN infection of Huh7.5.1 cells. Shown are light microscopy images of cells and 
immunofluorescence (IFA) staining of DEN pr/M (MOI= 1; 48 h rs post-infection) using the 2H2 antibody 
(red). 
 
 
 
4.3.3    Calculating an IC50 and CC50 for the Two “Lead” Compounds. 
 
 
 
 
After confirming that Streptovitacin A and Nagilactone C inhibited the infection of Huh7.5.1 
cells by means of IFA, we then attempted to further characterize these compounds by creating 
inhibitory curves to calculate the IC50 and CC50 values (Figure 14). To construct these curves we 
infected cells in the presence of serial dilutions of compounds.  Mycophenolic acid was used as a 
control for this experiment and the IC50  value that we obtained from the curve (0.8uM Figure 
14A) is analogous to the value provided in previous research (7).  Streptovitacin A had a similar 
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dose response as mycophenolic acid and therefore a similar IC50 (Figure 14B).   Even though the 
IC50 value was slightly higher for Nagilactone C (~2μM as we expected from the previous IFA 
experimental results), it is still in proximity to the mycophenolic acid. The CC50 value for 
streptovitacin A was 2.23uM, but we could not determine a CC50 value for nagilactone C since 
there was no cytotoxicity at 10μM, our maximum possible concentration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Inhibitory concentration IC50 of two inhibitors identified in the preliminary screening of 
264 NCI compounds. Inhibitory curves of a known DEN inhibitor, mycophenolic acid (A); 3977 B11 
(streptovitacin A) (B); and 3977 G11 (nagilactone C) (C). The percentage of inhibition was calculated using 
a formula %inhibition= (RLUexp-RLUmin)/(RLUmax-RLUmin)*100 where RLUexp represents the 
luciferase counts obtained from inhibitor treated wells, and RLUmax typically comes from uninfected wells 
whereas RLUmin comes from DEN infected and treated with DMSO. IC50 is defined as concentrations 
needed to achieve 50% inhibition in vitro. 
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Figure 15. Cytotoxicity concentration CC50of the two inhibitors identified the a preliminary screening 
of 264 NCI compounds. % Survival curves of a known DEN inhibitor, mycophenolic acid (A); 3977 B11 
(streptovitacin A) (B); and 3977 G11 (nagilactone C) (C). The percentage of survival was calculated using a 
formula %survival= RLUexp/(RLUmax*100 where RLUexp represents the luciferase counts obtained from 
inhibitor treated wells, and RLUmax typically comes from DMSO treated wells. CC50 is defined as 
concentrations needed to achieve 50% survivalin vitro. CC50 is indicated with each compound. 
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Now that we had determined the IC50 and CC50of these inhibitory compounds we decided to 
further characterize by evaluating their inhibitory properties on the other three serotypes of DEN. 
As shown in Figure 15, 2 μM of both streptovitacin A and mycophenolic acid and to a lesser 
extent nagilactone C were able to inhibit the infection of DV2, 3 and 4.  Interestingly DV1 did 
not show the same inhibition, however, the cells in the untreated IFA did not show as strong of a 
signal as did the other three serotypes. 
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Figure 16. Streptovitacin A and Nagilactone C inhibited the infection of all serotypes of DEN on 
Huh7.5.1 cells.  Shown are light microscopy images of cells and immunofluorescence (IFA) staining of DEN 
pr/M (MOI= 1; 48 hrs post-infection) using the 2H2 antibody (red). 
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In addition to evaluating the inhibitor effect on all four serotypes of DEN, we also characterized 
the ability of streptovitacin A and nagilactone C to block the infection of two other RNA viruses, 
hepatitis C (HCV) and New Castle Disease Virus (NDV).  The HCV clone that we used to infect 
has a luciferase gene insert that will be expressed during infection and similarly the NDV virus 
has a GFP insert (Figure 17).  The inhibitory results from both of these viruses are comparable to 
those observed in the previous experiment, streptovitacin A and mycophenolic acid inhibited 
infection almost completely whereas nagilactone C inhibited but to a lesser extent. 
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Figure 17. Streptovitacin A and Nagilactone C inhibited the HCVcc and NDV-GFP infection of 
Huh7.5.1 cells.   
(A) Huh7.5.1 cells were infected with a h epatitis C luciferase expressing clone in the presence or 
absence of compounds. (B)Huh7.5.1 cells were infected with a New castle virus – green fluorescence 
expressing clone in the presence or absence of compounds.  Mycophenolic acid, a known inhibitor of DEN 
infection was used as a control. 
 
A.
 
 
B.
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5.0 DISCUSSION 
 
 
 
 
 
 
Despite the severe disease burden of dengue infection each year, no va ccines or antivirals have 
been  found  to  treat  this  disease.    In  this  study,  we  have  successfully  established  a robust 
technological high-throughput screening assay to find compounds that prevent the cytopathic 
effect of dengue on he patocytes. We hypothesized that novel inhibitors of DEN infection could 
be identified through this larger scale screening assay.   These inhibitory compounds could be 
used to elucidate cellular pathways that DEN may utilize for establishing its infection and possibly in 
the long term as new therapeutics to combat the infection. 
We  have  optimized  the  CPE-based  assay  using  a  range  of  virus  MOIs  for  various 
durations to find the largest signal-to-background ratio.  Having a broad window for signal-to- 
background permitted us to indentify compounds that have a potent effect in preventing this 
cytopathic effect.  At a MOI of 1 and a duration of 72 hou rs we observed the largest signal-to- 
background ratio (>16) in the shortest amount of time.  Using IFN-α as a positive control under 
these experimental conditions, we see that there is less that 50% inhibition of cell death.  We 
reasoned that this would be an appropriate MOI and time period to demonstrate the potency of 
the compounds as a strong inhibitor of dengue infection like IFN-α could not inhibit at this 
concentration. 
This assay is advantageous to current methodology because it simultaneously filters out 
compounds that inhibit infection but at the same time are toxic to cells. This simultaneous effect 
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is demonstrated with Bafilomycin A in figure 11.  In a TCID50/ml assay previously carried out 
on Baf A showed almost complete inhibition of infection, however because it is somewhat toxic 
it would be screened out in our assay. One obvious limitation to this assay is that rather than the 
compounds directly inhibiting virus infection, they could be acting on and inhibiting a pathway 
or mechanism required for cell death.  However, data validation is crucial in modern high- 
throughput  screening.  By  setting  a  relatively  stringent  criterion,  we  anticipate  to  only 
characterize those compounds that potently inhibit DEN infection without high levels of 
cytotoxicity. The proposed functional characterizations include IFA-based detection of viral 
protein pr/M, determination of CC50 and IC50 as well as therapeutic window. 
We screened a 264 compound library and found a number of hits that inhibit at least 50% 
 
of this cytopathic effect.  Further evaluation of these positive hits with an IFA showed that two 
compounds, streptovitacin A and nagilactone C, block dengue infection as is demonstrated in 
Figure 9.   W e then did a dose response curve to find the   IC50  for streptovitacin A and 
nagilactone C and found the IC50 for each was comparable to mycophenolic acid, a known 
inhibitor of dengue (7).  Unfortunately were not able to determine the CC50 value as our highest 
concentration available for each compound did not cause cytotoxicity. 
Streptovitacin A and nagilactone C have been extensively studied for their use as possible 
antitumor reagents.  The chemical structures for both of these compounds are provided in Figure 
18.   Streptovitacin A is a hydrolated form of cycloheximide, a strong antifungal inhibitor 
compound produced by the bacterium Streptomyces griseus, and also functions as an inhibitor of 
protein biosynthesis (25).   However unlike its parental compound, streptovitacin A does not 
cause  a  depression  of  DNA  or  RNA  synthesis  and  has  low  cytotoxicity  and  thus  it  was 
previously studied as a possible antitumor agent.  In addition this compound was used to study 
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the life cycles of other SS-RNA viruses including poliovirus and coxackievirus B (15).   The 
effects of this compound was also demonstrated on the vaccinia DNA virus and reovirus, a DS- 
RNA virus (6) 
Nagilactone C is a natural plant compound produced by the genus Podocarpus and has 
been shown to have antifungal properties (14), inhibit plant growth and display insecticidal 
properties(2).   In 2004, Chan et al. elucidated the inhibitory properties of nagilactone C using 
HeLa cells.  T hey found that this potent protein synthesis inhibitor acts by blocking eEF-1α- 
dependent loading of aminoacyl-tRNA into the ribosomal A site, as well as peptidyl 
transferase(2).  Interestingly when they added nagilactone C to HeLa cells protein synthesis was 
decreased by 95%, however when they removed the compound and replaced the media they 
observed a reversal in the inhibition. 
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Streptovitacin A Nagilactone C 
 
Figure 18. Chemical structures of the two compounds identified to inhibit dengue infection,  
streptovitacin A and nagilactone C. 
 
 
 
 
Our  preliminary  study  has  demonstrated  that  the  CPE-based  screening  assay  we 
developed is highly robust and highly reproducible yielding a Z’ of nearly 0.9 within the same 
experiment.  The Z-factor is a statistical parameter commonly accepted in HTS to show the ability of an 
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assay to identify “hits”.  The Z-factor is reported as a number 0 to 1 and anything over 0.5 is considered 
excellent (35).  We therefore reason that this method can be used to identify novel inhibitors of 
DEN infection. Unfortunately, the current study is of limited scope given that we only performed 
the initial screening using a 264 compound library. To prove this assay is adaptable to a high- 
throughput manner, in the future we plan to screen a natural product library from TimTec (700 
compounds, gift of  Dr. Nicholas Sluis-Cremer) and a homemade mini pathway inhibitor library 
(100 inhibitors) comprising inhibitors of commons kinases, cell trafficking, cell death). The first 
library will provide an excellent non-biased library to verify the assay robustness. The goal of 
screening the mini-pathway inhibitor library is to identify cellular pathways that DEN may 
utilize for establishing its infection. 
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